<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Diazoxide</strong></td></tr><tr><th>Accession Number</th><td><strong>DB01119</strong>&#160; (APRD00914)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>A benzothiadiazine derivative that is a peripheral vasodilator used for hypertensive emergencies. It lacks diuretic effect, apparently because it lacks a sulfonamide group. [PubChem]</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB01119/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB01119/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01119.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01119.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01119.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01119.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01119.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB01119">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Eudemine</td><td>Mercury</td></tr><tr><td>Hyperstat</td><td>Schering</td></tr><tr><td>Proglycem</td><td>Gate</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/sodium-chloride-symporter-inhibitors">Sodium Chloride Symporter Inhibitors</a></li></ul></td></tr><tr><th>CAS number</th><td>364-98-7</td></tr><tr><th>Weight</th><td>Average: 230.671<br>Monoisotopic: 229.991675875</td></tr><tr><th>Chemical Formula</th><td>C<sub>8</sub>H<sub>7</sub>ClN<sub>2</sub>O<sub>2</sub>S</td></tr><tr><th>InChI Key</th><td>GDLBFKVLRPITMI-UHFFFAOYSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C8H7ClN2O2S/c1-5-10-7-3-2-6(9)4-8(7)14(12,13)11-5/h2-4H,1H3,(H,10,11)</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">7-chloro-3-methyl-4H-1$l^{6},2,4-benzothiadiazine-1,1-dione</div></td></tr><tr><th>SMILES</th><td><div class="wrap">CC1=NS(=O)(=O)C2=C(N1)C=CC(Cl)=C2</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Heterocyclic Compounds</td></tr><tr><th>Class</th><td>Thiadiazines</td></tr><tr><th>Subclass</th><td>Benzothiadiazines</td></tr><tr><th>Direct parent</th><td>Benzothiadiazines</td></tr><tr><th>Alternative parents</th><td>Chlorobenzenes; Aryl Chlorides; Sulfonic Acids and Derivatives; Polyamines; Organochlorides</td></tr><tr><th>Substituents</th><td>chlorobenzene; aryl chloride; benzene; aryl halide; sulfonic acid derivative; polyamine; organochloride; organohalogen; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the benzothiadiazines. These are organic compounds containing a benzene fused to a thiadiazine ring (a six-member ring with two nitrogen atoms and a sulfur atom).</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>Used parentally to treat hypertensive emergencies. Also used to treat hypoglycemia secondary to insulinoma.</td></tr><tr><th>Pharmacodynamics</th><td>Diazoxide is a potassium channel activator, which causes local relaxation in smooth muscle by increasing membrane permeability to potassium ions. This switches off voltage-gated calcium ion channels which inhibits the generation of an action potential.</td></tr><tr><th>Mechanism of action</th><td>As a diuretic, diazoxide inhibits active chloride reabsorption at the early distal tubule via the Na-Cl cotransporter, resulting in an increase in the excretion of sodium, chloride, and water. Thiazides like diazoxide also inhibit sodium ion transport across the renal tubular epithelium through binding to the thiazide sensitive sodium-chloride transporter. This results in an increase in potassium excretion via the sodium-potassium exchange mechanism. The antihypertensive mechanism of diazoxide is less well understood although it may be mediated through its action on carbonic anhydrases in the smooth muscle or through its action on the large-conductance calcium-activated potassium (KCa) channel, also found in the smooth muscle. As a antihypoglycemic, diazoxide inhibits insulin release from the pancreas, probably by opening potassium channels in the beta cell membrane.</td></tr><tr><th>Absorption</th><td>Readily absorbed following oral administration.</td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td>Very high (more than 90%) to serum proteins.</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Hepatic.</p></td></tr><tr><th>Route of elimination</th><td>Proglycem is extensively bound (more than 90%) to serum proteins, and is excreted in the kidneys.</td></tr><tr><th>Half life</th><td>28 &#177;8.3 hours in normal adults.</td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td>Oral LD<sub>50</sub> in rat and mouse: 980 mg/kg and 444 mg/kg, respectively.</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>1.0</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.5923</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              -
        </td>
        <td>0.5765</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Non-substrate
        </td>
        <td>0.6817</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.6924</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.6927</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8107</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.5606</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.8064</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-substrate</td>
        <td>0.5774</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Inhibitor</td>
        <td>0.9108</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9071</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Inhibitor</td>
        <td>0.8932</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9025</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.831</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.7977</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.7888
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.8304
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            1.0
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.3408 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9233
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.9271
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Teva branded pharmaceutical products r&amp;d inc</li>
<li>Abraxis pharmaceutical products</li>
<li>Schering corp sub schering plough corp</li>
<li>Teva global respiratory research llc</li></ul></td></tr><tr><th>Packagers</th><td><ul><li>Ivax Pharmaceuticals</li>
<li><a href="http://www.medisca.com">Medisca Inc.</a></li>
<li><a href="http://www.tevapharm.com">Teva Pharmaceutical Industries Ltd.</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Capsule</td><td>Oral</td><td></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB00436">Bendroflumethiazide</a></td><td>Significant hyperglycemic effect</td></tr><tr><td><a href="/drugs/DB00672">Chlorpropamide</a></td><td>Antagonism. </td></tr><tr><td><a href="/drugs/DB00310">Chlorthalidone</a></td><td>Significant hyperglycemic effect</td></tr><tr><td><a href="/drugs/DB01320">Fosphenytoin</a></td><td>Diazoxide decreases the hydantoin effect</td></tr><tr><td><a href="/drugs/DB01016">Glyburide</a></td><td>Antagonism. </td></tr><tr><td><a href="/drugs/DB00999">Hydrochlorothiazide</a></td><td>Significant hyperglycemic effect</td></tr><tr><td><a href="/drugs/DB00808">Indapamide</a></td><td>Significant hyperglycemic effect</td></tr><tr><td><a href="/drugs/DB00252">Phenytoin</a></td><td>Diazoxide decreases the efficacy of phenytoin. </td></tr><tr><td><a href="/drugs/DB00519">Trandolapril</a></td><td>Diazoxide may increase the hypotensive effect of Trandolapril. Monitor for changes in blood pressure.</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table>